HUPERZINE A DERIVATIVES, THEIR PREPARATION AND THEIR USE

Abstract: The present invention relates to novel huperzine A derivatives of formula (II), wherein Y is or R'' and Y together form =CH; R is (C 1 -C 5 ) alkyl, wherein n is 0 or 1, X is H, (C 1 -C 5 ) alkyl; (C 1 -C 5 ) alkyloxy; nitro, halogen, carboxy, alkyloxycarbonyl, hydroxymethyl, hydroxy, amino substituted by bis-(C 1 -C 5 ) alkyl; -(CH 2 ) m COOZ, wherein m=0-5, Z is H or (C 1 -C 5 ) alkyl; -CH=CH-G, wherein G is phenyl, furanyl, carboxy, alkyloxycarbonyl; and dihydro- or tetrahydro-pyridyl substituted by (C 1 -C 5 ) alkyl at the nitrogen atom; R' is H, (C 1 -C 5 ) alkyl, pyridoyl, benzoyl substituted by (C 1 -C 5 ) alkyloxy; R'' is H or (C 1 -C 5 ) alkyl; processes for their use as acetylcholinesterase inhibitor.

Description: The present invention relates to semi-synthesis of natural product, and particularly to alkaloids and analogues thereof. In the past ten years, considerable research has been conducted in relation to the application of choline esterase inhibitor to enhance the function of the intracerebral cholinergic system for the treatment of presenile dementia. Although delightful results of research have been obtained, there still exists some defects; at the time of producing the treatment effect, there occurs a relatively serious toxic side reaction; and the duration of the effect is relatively short. In recent years, workers in China have isolated from a Chinese herb, Lycopodium serratum Thunb., a new alkaloid huperzine A (5R, 9R, 11E)-5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-5,9-methylene cycloocta [b] pyridyl-2(1H)-one having the formula (I) Upon a pharmacological study it was proved that it exhibits highly effective reversible anticholinesterase activity, and has selective inhibitory effect on intracerebral acetylcholinesterase (U.S. Patent No. 5177082). In foreign countries modification of the structure of huperzine A has been carried out and analogues of huperzine A have been synthesized in hopes of discovering therefrom compounds having anticholin-esterase activity [J. Org. Chem. 56, 1991(4636-4645)] and finding a method of synthesizing huperzine A [U.S. Patent No. 4929731]. However, neither a good method nor an analogue having a better effect has been found so far. We have made use of the excellent resources of Chinese herbs in China to design a semi-synthesis starting from huperzine A, in the hope of finding among a great variety of huperzine A derivatives compounds having better treatment effect and lower toxicity than the existing huperzine A. Thus, according to one aspect, the present invention provides a huperzine A derivative of the formula: wherein: either Y is -C=O and R 11 is H or C 1-5 alkyl; or Y and R 11 together form the group =CH; R is n=0 or 1; and X is hydrogen, C 1 -C 5 lower alkyl, C 1 -C 5 lower alkyloxy, nitro, halogen, carboxy, alkyloxycarbonyl, hydroxymethyl, hydroxy, amino substituted by bis-C 1 -C 5 lower alkyl; or a -(CH 2 ) m COOZ group, m=0-5, Z is hydrogen or C 1 -C 5 lower alkyl; or a -CH=CH-G group, G is phenyl, furanyl, carboxy or alkyloxycarbonyl; or a dihydro or tetrahydropyridyl substituted by C 1 -C 5 lower alkyl at the nitrogen atom; R 1 is hydrogen, C 1 -C 5 lower alkyl, pyridoyl or benzoyl substituted by C 1 -C 5 lower alkyloxy; R 11 is hydrogen and C 1 -C 5 lower alkyl. When Y is C=O, R is n=0 or 1; and X is hydrogen, C 1 -C 5 lower alkyloxy, carboxy, alkyloxycarbonyl, pyridyl, dihydro or tetrahydropyridyl substituted by C 1 -C 5 lower alkyl at the nitrogen atom; a -(CH 2 ) m COOZ group, m=0-5, Z is hydrogen or C 1 -C 5 lower alkyl; or a -CH=CH-G group, G is phenyl, furanyl, carboxy or alkyloxycarbonyl; R 1 is hydrogen, C 1 -C 5 lower alkyl, pyridoyl or benzoyl substituted by C 1 -C 5 lower alkyloxy; R 11 is hydrogen and C 1 -C 5 lower alkyl. When R 11 and Y together form the group =CH, R is n=0, X is hydrogen, C 1 -C 5 lower alkyl, C 1 -C 5 lower alkyloxy, nitro, halogen, hydroxy, hydroxymethyl, amino substituted by bis-C 1 -C 5 lower alkyl; or a -CH=CH-G group, G is phenyl or furanyl; R 11 is hydrogen or C 1 -C 5 lower alkyl. Such huperzine A derivatives of the present invention can be prepared by the following steps: 1. Using alcohols such as ethanol as extraction solvent, from the plant Lycopodium serratum Thunb., the residue obtained is concentrated, and then treated with an inorganic acid (such as hydrochloric acid). The aqueous layer is neutralized with alkali (such as ammonia water, NaOH), after which an organic solvent (such as chloroform) is used to extract the total alkaloid. After the treatment, separation by layer chromatography is carried out to produce the compound of the formula (I). 2. After condensation is carried out between the compound of the formula (I), and the corresponding substituted aldehyde or the corresponding substituted acyl chloride or acid anhydride in anhydrous solvent, a compound of the formula (II) is obtained. Huperzine A derivatives: Pharmacological effect of huperzine A derivatives: In the present invention a colorimetric method reported by Ellman was used to determine the effect of inhibition of the pharmaceutical on enzyme activity. The total volume of the solution of the enzyme activity reaction was 4 ml, which contained 0.3 mmol/L of acetylcholin iodide (acetylcholinesterase substrate), or 0.4 mmol/L of butyrylcholin iodide (butyrylcholinesterase substrate), 1 ml of the buffer solution of 25 mmol/L of phosphate of pH 7.4, and water to make up to 4 ml (including the amount of the enzyme solution and the testing reagent added afterwards). After the solution was kept at 37°C for 5 minutes, 0.1-0.2 ml of enzyme solution (red cell membrane or serum of rat) was added, or 0.1-0.3 ml of the testing reagent was added at the same time. The solution was kept at the same temperature for another 8 minutes. Then 1 ml of 3% of sodium lauryl sulphate was added to terminate the reaction. Finally 1 ml of 0.2% 5,5-dithio-2,2'-nitro-benzoic acid solution was added for developing. "721" spectrophotometer was used to determine the density of light at 440 nm. A solution without addition of the pharmaceutical to inhibit the enzyme activity was used as a control (100%). A diagram was plotted with the percentage of the remaining enzyme activity against gram molecule concentration of the pharmaceutical, so as to obtain the dose of the pharmaceutical at 50% of inhibition of the enzyme activity, i.e., IC 50 . The results of the test showed that all the derivatives exhibited inhibition effect on acetylcholinesterase; derivatives No. 1, No. 17, No. 18 and No. 19 exhibited remarkable inhibition effect on acetylcholinesterase; their effect was slightly weaker than that of huperzine A, but apparently stronger than that of physostigmine and galanthamine. They exhibited weaker inhibition effect on butyrylcholinesterase (pseudo enzyme) than huperzine A. Derivatives No. 1 and No. 17 exhibited greater selective inhibition effect on acetylcholinesterase than huperzine A (see Tables 1, 2 and 6). A study on kinetics of enzyme indicated that the combination of derivatives No. 17, No. 18 and No. 19 respectively with acetylcholinesterase was reversible. The two memory model test, mouse passive escape operation (Platform jumping method) and 8-arm maze spatial distinction operation of rat, indicated that both derivatives No. 18 and No. 19 exhibited very strong effect, similar to that of the compound of formula (I), on improving memory (see Tables 3 and 4). The critical toxicity test on mice indicated that LD50 of derivatives No. 18 and No. 19 were smaller than, only 1/3 of, that of the compound of formula (I) (see Table 5). In-vitro anticholinesterase effect of huperzine A derivatives (determined by colorimetric method) Compound No. concentration for inhibition of 50% of enzyme activity (IC 50 , µM) IC 50 ratio BuChE/AChE acetylcholinesterase (AChE) butyrylcholinesterase (BuChE) 1 0.348 380.19 1092.5 2 9.05 >346.7 3 3.63 >331.1 4 >12.88 58.9 5 >10.96 >275.4 6 >12.3 >309.1 17 0.172 199.5 1159.9 18 0.151 107.2 709.9 19 0.145 104.7 722.1 10 >15.85 109.6 11 >14.45 363 compound (I) 0.06309 63.09 1000 Physostigmine 0.251 1.259 5.02 galanthamine 1.995 12.59 6.3 AChE taken from rat's red cell membrane. BuChE taken from rat's serum. In-vitro anticholinesterase effect of huperzine A derivatives Compound No. MW concentration for inhibition of 50% of enzyme activity (IC 50 , µM) IC 50 ratio BuChE/AChE acetylcholinesterase (AChE) butyrylcholinesterase (BuChE) huperzine A 242 0.0977 100.0 1023.3 1 342 0.3475 380.2 1094.1 12 376 0.1259 251.2 1995.2 15 390 0.6310 502.0 795.6 17 428 0.1718 199.5 1161.2 18 376 0.1514 107.2 708.2 19 406 0.1445 104.7 724.6 20 346 0.1778 125.9 708.1 21 420 0.1413 158.5 1121.3 22 406 0.1259 125.9 1000.0 23 362 0.2512 199.5 794.2 24 362 0.1000 158.5 1585.0 25 378 0.1585 251.2 1584.9 27 356 0.1259 100.0 794.3 MW: molecular weight AChE taken from homogenate of rat's cortex. BuChE taken from rat's serum. Critical toxicity of huperzine A derivatives on mice (Bliss method) Compound mg/kg p.o. (95% confidence limit) LD 50 LD 50 compound (I) 3.1(3.5 - 3.8) 4.6(4.2 - 5.1) derivative No. 18 9.6(7.3 - 12.5) 14.4(12.9 - 16.4) derivative No. 19 11.1(9.6 - 12.9) 14.1(15.5 - 20.5) Test of each pharmaceutical was carried out using 4-5 dosage group. Mortality within 7 days was observed. In-vitro anticholinesterase effect of huperzine A derivatives Compound No. inhibition activity AChE BuChE 10(µM) BuChE/AChE 1(µM) IC 50(M) (18) 90.2 8.4×10 -8 0 >500 (20) 83.7 9.4×10 -8 0 >500 (21) 84.9 1.0×10 -7 0 >500 (22) 68.7 0 (23) 34.4 0 (15) 60.8 0 (24) 78.3 2.8×10 -7 0 >100 (25) 62.0 0 (27) 84.0 1.1×10 -7 3.3 >500 (26) 79.7 1.8×10 -7 1.1 >300 (16) 80.7 2.1×10 -7 1.8 >200 (14) 76.4 3.6×10 -7 2.5 >100 (44) 85.6 1.1×10 -7 1.8 >500 (45) 87.0 1.0×10 -7 1.8 >500 (46) 78.7 2.9×10 -7 1.2 >100 E-2020 86.2 6.6×10 -8 2.9 >500 huperzine A 88.3 1.2×10 -7 0 >500 The results of the above pharmacological study show that derivatives No. 17, No. 18 and No. 19 are highly effective selective inhibitors of acetylcholinesterase and have lower critical toxicity than compound (I). Hence, it can be deduced that they have prospect of clinical application and development for use in the treatment of relieving serious amyasthenia and of dysmnesia caused by failure in central cholinergic system. Example 1. Preparation of derivative No. 2 Compound (I) (0.50 mmole) into 5 ml three-neck flask was weight out. 20 ml of anhydrous pyridine was added to dissolve compound (I). While cooling in ice-bath, phenyl acetyl chloride (0.55 mmole) was added dropwise. Then the whole mixture was stirred overnight at room temperature (25°C). When thin-layer chromatography indicated substantial disappearance of the starting materials, the reaction was stopped. Pressure was reduced by means of water pump to vaporize pyridine. Separation was carried out using silica gel layer chromatography. Elution was carried out with dichloromethane : acetone : methanol = 5 : 45 : 5 to produce the crude product, which was recrystallized using a mixed solvent of acetone and petroleum ether to produce the product with 75% yield. UV λ max =229nm (∈=17360) λ max =316nm(∈=9320) [α] 25°C / D = 29.43 1 HNMR: [CDCl 3 ] 3H 6.31(1H,d,J=9.9Hz) 4H 7.20 (1H,d,J=9.9Hz) 10H 2.89(2H,m) 9H 3.52(1H,m) 8H 5.38(1H,d,J=5.0Hz) 14-H 1.62(3H,d,J=6.7Hz) 13-H 5.08(1H,q,J=6.7Hz) 6-H 2.15,2.45(2H,m) 12-H 1.50(3H,s) 2',4'-H 7.36(2H,m) 3',5'-H 7.29(2H,m) 6'-H 7.24(1H,m) 7'-H 3.59(s) MS(m/z) 360(M + ) 345 269 252 227 224 210(100%) 91 mp: 171-173°C IR: υ max 3280, 1660(s), 1620(s), 1550, 1450, 1350, 1300, 1175, 1130, 840, 620 cm -1 The same process was used to prepare derivatives No. 3, No. 5, No. 6, No. 7, No. 8, No. 9, No. 10, No. 11, and No. 13. Example 2. Preparation of derivative No. 4 Compound (I) (0.5 mmole) into 50 ml three-neck flask was weight out. 20 ml of anhydrous pyridine to dissolve compound (I) was added. While cooling in ice-bath, DBU (0.6 mmole) was first added, and then 0.55 mmole of hydrochloric acid pyridine-2-formyl chloride was added. The whole mixture was placed overnight at room temperature. When thin-layer chromatography determination indicated substantial completion of the reaction, pressure was reduced by means of water pump to vaporize pyridine. Separation was carried out using silica gel layer chromatography. Elution was carried out with dichloromethane : acetone : methanol = 50 : 45 : 5 to produce the crude product, which was recrystallized using a mixed solvent of acetone and petroleum ether to produce the product with 74% yield. UV λ max =226nm (∈=1.35×10 4 ) λ max =264nm (∈=5.4×10 3 ) λ max =315nm (∈=5730) [α] D = 77.85° 1 HNMR: [CDCl 3 ] 3-H 6.36(1H,J=9.2Hz) 4-H 7.44(1H,J=9.2Hz) 10-H 3.05(2H,m) 9-H 3.74(1H,m) 8-H 5.42(1H,d,J=4.7Hz) 14-H 1.65(3H,d,J=6.6Hz) 13-H 5.35(1H,q=6.6Hz) 6-H 2.42(2H,s) 12-H 1.55(3H,s) 2'-H 8.58(1H,m) 4'-H 7.85(1H,m) 5'-H 7.48(1H,m) 6'-H' 8.15(1H,m) MS(m/z) 347(M + ), 241(100%) 169, 149, 106, 95, 79, 71, 55 mp: 170-171°C IR: υ max 3450, 2900, 1660(s), 1615(s), 1530(s), 1460, 1300, 1180, 1140, 1000, 830, 750 cm -1 The same process was used to prepare derivatives No. 12 and No. 14. Example 3. Preparation of derivative No. 19 Compound (I) (0.5 mmole) was weight out into 50 ml three-neck flask. Anhydrous ethanol and 4,6-dimethoxy-2-hydroxy benzaldehyde (0.51 mmole) were added. The mixture was heated slightly under reflux. Through a water segregator part of the ethanol was vaporized continuously. The solvent in the reaction was constantly replenished. The reaction was carried out for several hours and the reaction state was constantly determined by means of thin-layer chromatography. When the reaction was completed, the pressure was reduced to remove the ethanol to produce a solid crude product, which was recrystallized using a mixed solvent of acetone and petroleum ether to produce the product with 92% yield. The same process was used to prepare derivatives No. 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, and 43. Derivative No. 19 m.p. 207-210°C MS: m/z 406(M + ) 391(M + -CH 3 ), 351(M + -C 4 H 7 ) 1 H NMR (CDCl 3 ) 1-H 13.12(1H,br,s) 3-H 6.41(1H,d,J=9.1Hz) 4-H 7.25(1H,d,J=9.1Hz) 6-H 2.85(2H,s) 8-H 3.45(1H,d,J=4.7Hz) 9-H 3.61(1H,m) 10-H 2.85(2H,m) 12-H 3 1.60(3H,s) 13-H 5.22(1H,q,J=7.7Hz) 14-H 3 1.25(3H,d,J=7.7Hz) 2'-OH 14.58(1H,br,s) 3'-H 5.57(1H,s) 4'-OCH 3 3.79(3H,s) 5'-H 5.85(1H,s) 6'-OCH 3 3.70(3H,s) 7'-H 8.15(1H,s) IR: υ max 3480(m), 2960(s), 2930(s), 2870(s), 1670(s), 1620(s), 1540(s), 1450(s), 1330(s), 1300(s), 1218(sh), 1186(m), 1155(s), 1110(s), 1080(m), 1050(m), 1000(m), 930(m), 840(s), 730(m), 670(m), 610(m), 520(s) cm -1 . Derivative No. 20 1 H NMR (CDCl 3 ): 1-H 12.72(1H,br,s) 3-H 6.34(1H,d,J=9.4Hz) 4-H 7.11(1H,d,J=9.4Hz) 6 a -H 2.79(1H,d,J=16.0Hz) 6 b -H 2.75(1H,d,J=16.0Hz) 8-H 5.41(1H,d,J=5.0Hz) 9-H 3.63(1H,m) 10 a -H 2.95(1H,dd,J=16.6, 4.9Hz) 10 b -H 2.27(1H,d,J=16.6Hz) 12-H 1.57(3H,s) 13-H 5.07(1H,q,J=6.8Hz) 14-H 1.55(3H,d,J=6.8Hz) 2'-OH 13.77(1H,br,s) 3'-H 6.94(1H,d,J=8.4Hz) 4'-H 7.30(1H,t with small splitts, J=8.4Hz) 5'-H 6.85(1H,t with small splitts, J=7.4Hz) 6'-H 7.22(1H,dd,J=7.4, 1.6Hz) 7'-H 8.31(1H,s) MS: 346(M + ), 331, 317, 303, 291, 253, 239, 226, 210, 197, 184, 167, 128, 121, 97. IR: υ max 3420, 2900, 1660, 1620, 1580, 1560, 1500, 1460, 1420, 1380, 1350, 1280, 1205, 1150, 1120, 1080, 1010, 970, 910, 840, 790, 755(s), 650, 630, 610, 520 cm -1 Derivative No. 21 1 H NMR (CDCl 3 ) 1-H 12.87(1H,br,s) 3-H 6.32(1H,d,J=9.4Hz) 4-H 7.07(1H,d,J=9.4Hz) 6 a -H 2.79(1H,d,J=16.0Hz) 6 b -H 2.75(1H,d,J=16.0Hz) 8-H 5.43(1H,d,J=5.0Hz) 9-H 3.63(1H,m) 10 a -H 2.97(1H,dd,J=16.0, 4.0Hz) 10 b -H 2.18(1H,d,J=16.0Hz) 12-H 1.58(3H,s) 13-H 5.14(1H,q,J=6.8Hz) 14-H 1.57(3H,d,J=6.8Hz) 2',6'-2H 7.04(2H,s) 7'-H 8.25(1H,s) 3',5'-2(OCH 3 ) 3.87(6H,s) 4'-OCH 3 3.84(3H,s) MS: 420(M + ), 405(M + -CH 3 ), 391, 365, 351, 313, 284, 239, 226, 210, 196, 181, 140, 124. IR: υ max 2940, 1660(s), 1590, 1560, 1500, 1565, 1420, 1370, 1330, 1300, 1230, 1190, 1130(s), 1005, 960, 930, 840, 770, 735, 725, 660, 605, 540, 530 cm -1 . Derivative No. 22 1 H NMR(CDCl 3 ): 1-H 13.03(1H,br,s) 3-H 6.34(1H,d,J=9.4Hz) 4-H 7.14(1H,d,J=9.4Hz) 6-H 2 2.73(2H,s) 8-H 5.39(1H,d,J=4.7Hz) 9-H 3.61(1H,m) 10 a -H 2.94(1H,dd,J=16.8, 4.9Hz) 10 b -H 2.27(1H,d,J=16.8Hz) 12-H 1.55(3H,s) 13-H 5.09(1H,q,J=6.8Hz) 14-H 1.54(3H,d,J=6.8Hz) 2'-OH 14.39(1H,br.s) 3'-OCH 3 3.87(3H,s) 4'-OCH 3 3.85(3H,s) 5'-H 6.43(1H,d,J=8.7Hz) 6'-H 6.91(1H,d,J=8.7Hz) 7'-H 8.14(1H,s) MS: 406(M + ), 391(M + -CH 3 ), 373, 351, 239, 226, 197, 182, 167, 139, 101 IR: υ max 3450-3350(br), 2940(m), 1660(s), 1620(s), 1555, 1510, 1455, 1415, 1290, 1270(s), 1210, 1110(s), 1060, 970, 930, 835, 785, 695, 675, 640, 625 cm -1 . Derivative No. 23 1 H NMR(d 6 -DMSO) : 1-H 11.48(1H,br,s) 3-H 6.13(1H,d,J=9.4Hz) 4-H 7.07(1H,d,J=9.4Hz) 6 a -H 2.68(1H,d,J=16.7Hz) 6 b -H 2.59(1H,d,J=16.7Hz) 8-H 5.48(1H,d,J=4.7Hz) 9-H 3.65(1H,m) 10 a -H 2.77(1H,dd,J=16.3, 4.0Hz) 10 b -H 2.28(1H,d,J=16.3Hz) 12-H 1.59(3H,s) 13-H 5.05(1H,q,J=6.8Hz) 14-H 1.60(3H,d,J=6.8Hz) 2'-OH 14.40(1H,br,s) 3'-H 6.18(1H,s) 4'-OH 10.09(1H,br,s) 5'-H 6.30(1H,d, with small splitts, J=8.4Hz) 6'-H 7.31(1H,d,J=8.4Hz) 7'-H 8.47(1H,s) MS: 362(M + ), 347, 319, 307, 242, 226, 210, 197, 167, 137. IR: υ max 3500-2800(br), 1665(s), 1625(s), 1605(s), 1550, 1540, 1450, 1345, 1300, 1230, 1180, 1120, 1080, 975 cm -1 . Derivative No. 24 1 H-NMR(CDCl 3 ): 1-H 13.09(1H,br,s) 3-H 6.37(1H,d,J=9.4Hz) 4-H 7.15(1H,d,J=9.4Hz) 6-H 2 2.76(2H,s) 8-H 5.42(1H,d,J=5.0Hz) 9-H 3.60(1H,m) 10 a -H 2.96(1H,dd,J=16.5, 4.9Hz) 10 b -H 2.32(1H,d,J=16.5Hz) 12-H 1.56(3H,s) 13-H 5.11(1H,q,J=6.8Hz) 14-H 1.58(3H,d,J=6.8Hz) 2'-OH 13.09(1H,br,s) 3'-OH 9.83(1H,br,s) 4'-H 6.68(1H,dd,J=8.1, 1.5Hz) 5'-H 6.57(1H,t,J=7.8Hz) 6'-H 6.91(1H,dd,J=7.6, 1.5Hz) 7'-H 8.08(1H,s) MS: 362(M + ), 347(M + -CH 3 ), 307, 253, 239, 226 197, 167, 149, 138, 137, 109, 92, 81. IR: υ max 3500-2800(br), 1660(s), 1625(s), 1545, 1460, 1370, 1275, 1240, 1120, 1080, 1060, 1020, 835, 775, 740(s), 640, 630, 525 cm -1 . Derivative No. 26 1 HNMR(CDCl 3 ): 1-H 13.10(1H,br,s) 3-H 6.33(1H,d J=9.4Hz) 4-H 7.12(1H,d,J=9.4Hz) 6-H 2 2.75(2H,s) 8-H 5.41(1H,d,J=4.8Hz) 9-H 3.62(1H,m) 10 a -H 2.95(1H,dd,J=16.5, 4.9Hz) 10 b -H 2.27(1H,d,J=16.5Hz) 12-H 3 1.57(3H,s) 13-H 5.08(1H,q,J=6.8Hz) 14-H 1.54(3H,d,J=6.8Hz) 2'-OH 14.36(1H,br,s) 3'-OCH 3 3.86(3H,s) 4'-H 6.83(1H,dd,J=7.9, 1.5Hz) 5'-H 6.76 (1H,t,J=7.9Hz) 6'-H 6.89(1H,dd,J=7.9, 1.5Hz) 7'-H 8.27(1H,s) MS: 376(M + ), 361, 346, 331, 306, 270, 253, 239, 226, 210, 197, 167, 152, 109, 106, 82. IR: υ max 3450-3360, 2940-2980, 1660(s), 1620(s), 1555, 1465(s), 1255(s), 1190, 1170, 1115, 1085, 970, 930, 840, 780, 740, 680, 640, 630, 520 cm -1 . Derivative No. 27 1 HNMR(CDCl 3 ): 1-H 12.80(1H,br,s) 3-H 6.34(1H,d,J=9.4Hz) 4-H 7.07(1H,d,J=9.4Hz) 6-H 2 2.72(2H,s) 8-H 5.40(1H,d,J=5.0Hz) 9-H 3.61(1H,m) 10 a -H 2.94(1H,dd,J=16.2, 3.6Hz) 10 b -H 2.17(1H,d,J=16.2Hz) 12-H 1.56(3H,s) 13-H 5.08(1H,q,J=6.8Hz) 14-H 1.57(3H,d,J=6.8Hz) 2',6'-2H 7.45(2H,dd,J=6.8, 1.4Hz) 3',5',8'-3H 7.30(3H,m) 4'-H 7.06(1H,m) 7'-H 6.99 (1H,d,J=15.9Hz) 9'-H 8.06(1H,d,J=8.1Hz) MS: 356(M + ), 341(M + -CH 3 ), 327, 301, 265, 237, 226, 210, 197, 167, 131, 115, 91, 77. IR: υ max 3600-3400(br), 2950-2850(br), 1660(s), 1632, 1620, 1550, 1465, 1445, 1300(m), 1175, 1115, 975, 825, 750(s), 690(s), 630, 620, 520 cm -1 . Derivative No. 28 1 HNMR(CDCl 3 ): 1-H 12.76(1H,br,s) 3-H 6.38(1H,d,J=9.3Hz) 4-H 7.12(1H,d,J=9.3Hz) 6 a -H 2.81(1H,d,J=16.0Hz) 6 b -H 2.78(1H,d,J=16.0Hz) 8-H 5.46(1H,br,s) 9-H 3.67(1H,m) 10 a -H 3.00(1H,dd,J=16.4, 4.5Hz) 10 b -H 2.31(1H,d,J=16.4Hz) 12-H 1.62(3H,s) 13-H 5.07(1H,q,J=6.6Hz) 14-H 1.60(3H,d,J=6.6Hz) 2'-OH 13.76(1H,br,s) 3'-H 6.94(1H,d,J=8.7Hz) 4'-H 7.29(1H,dd,J=8.7, 2.3Hz) 5',6',7',8'-4H 7.25(4H,m) 11'-H 8.30(1H,s) MS(m/z): 396(M + , 3%), 381(M + -CH 3 ,1), 226(2), 172(4), 144(2), 127(1), 115(5), 85(13), 71(22), 57(100). IR(KBr): 3408, 1660, 1626, 1479, 1280 cm -1 . Derivative No. 30 1 HNMR(CDCl 3 ): 1-H 10.92(1H,br,s) 3-H 6.42(1H,d,J=9.3Hz) 4-H 7.15(1H,d,J=9.3Hz) 6 a -H 2.82(1H,d,J=17.2Hz) 6 b -H 2.76(1H,d,J=17.2Hz) 8-H 5.47(1H,br,s) 9-H 3.69(1H,m) 10 a -H 2.99(1H,dd,J=16.0, 3.7Hz) 10 b -H 2.30(1H,d,J=16.0Hz) 12-H 1.63(3H,s) 13-H 5.07(1H,q,J=6.8Hz) 14-H 1.61(3H,d,J=6.8Hz) 3'-H 6.89(1H,d,J=6.8Hz) 4',6'-2H 7.42(2H,m) 7'-H 8.30(1H,s) MS(m/z): 426(M + +2,43%), 424(M + , 43), 411[(M + +2)-CH 3 ,42], 409(M + -CH 3 ,45), 369(11), 289(5), 253(18), 239(33), 226(100), 210(54), 197(47), 167(31), 128(31), 115(46), 91(32), 77(59), 57(81). IR(KBr): 3400, 1660, 1630, 1475, 1280, 823 cm -1 . Derivative No. 32 1 HNMR(CDCl 3 ): 1-H 12.70(1H,br,s) 3-H 6.39(1H,d,J=9.4Hz) 4-H 7.11(1H,d,J=9.4Hz) 6 a -H 2.81(1H,d,J=16.2Hz) 6 b -H 2.77(1H,d,J=16.2Hz) 8-H 5.45(1H,br,s) 9-H 3.67(1H,m) 10 a -H 2.99(1H,dd,J=16.7, 4.9Hz) 10 b -H 2.31(1H,d,J=16.7Hz) 12-H 1.62(3H,s) 13-H 5.06(1H,q,J=6.8Hz) 14-H 1.60(3H,d,J=6.8Hz) 2'-OH 13.80(1H,br,s) 3'-H 6.89(1H,d,J=8.7Hz) 4'-H 7.42(1H,dd,J=8.7, 2.4Hz) 6'-H 7.39(1H,d,J=2.4Hz) 7'-H 8.29(1H,s) MS(m/z): 392(M + +1,11%), 391(M + ,45), 376(M + -CH 3 ,60), 242(18), 226(53), 101(28), 83(53), 59(100). IR(KBr): 3419, 1660, 1616, 1549, 1336, 833 cm -1 . Derivative No. 33 1 HNMR(CDCl 3 ): 1-H 12.40(1H,br,s) 3-H 6.42(1H,d,J=9.5Hz) 4-H 7.15(1H,d,J=9.5Hz) 6 a -H 2.84(1H,d,J=16.3Hz) 6 b -H 2.77(1H,d,J=16.3Hz) 8-H 5.47(1H,br,s) 9-H 3.70(1H,m) 10 a -H 3.00(1H,dd,J=16.0, 4.9Hz) 10 b -H 2.39(1H,d,J=16.0Hz) 12-H 1.58(3H,s) 13-H 5.12(1H,q,J=6.8Hz) 14-H 1.63(3H,d,J=6.8Hz) 2'-OH 15.59(1H,br,s) 4'-H 8.16(1H,d,J=7.8Hz) 5'-H 6.77(1H,t,J=7.8Hz) 6'-H 7.46(1H,d,J=7.8Hz) 7'-H 8.24(1H,s) MS(m/z): 391(M + ,66%), 376(M + -CH 3 ,41), 356(45), 328(18), 288(14), 239(15), 226(100), 210(25), 197(22), 83(61). IR(KBr): 3431, 1662, 1633, 1529, 1352, 1242, 754 cm -1 . Derivative No. 34 1 HNMR(CDCl 3 ): 1-H 12.87(1H,br,s) 3-H 6.38(1H,d,J=9.6Hz) 4-H 7.13(1H,d,J=9.6Hz) 6-H 2 2.78(2H,s) 8-H 5.46(1H,br,s) 9-H 3.67(1H,m) 10 a -H 3.00(1H,dd,J=16.5, 4.9Hz) 10 b -H 2.32(1H,d,J=16.5Hz) 12-H 1.62(3H,s) 13-H 5.09(1H,q,J=6.7Hz) 14-H 1.59(3H,d,J=6.7Hz) 2'-OH 14.42(1H,br,s) 3'-OCH 3 3.90(3H,s) 4',6'-2H 6.86(2H,m) 7'-H 8.22(1H,s) MS(m/z): 412(M + +2,0.3%), 410(M + ,1.2), 395(M + -CH 3 ,0.5), 239(1.4), 216(2), 83(100). IR(KBr): 3421, 2933, 1660, 1618, 1471, 1253, 839 cm -1 . Derivative No. 35 1 HNMR(CDCl 3 ): 1-H 12.80(1H,br,s) 3-H 6.38(1H,d,J=9.3Hz) 4-H 7.13(1H,d,J=9.3Hz) 6-H 2 2.78(2H,s) 8-H 5.46(1H,br,s) 9-H 3.67(1H,m) 10 a -H 3.00(1H,dd,J=16.7, 5.1Hz) 10 b -H 2.32(1H,d,J=16.7Hz) 12-H 1.62(3H,s) 13-H 5.08(1H,q,J=6.8Hz) 14-H 1.59(3H,d,J=6.8Hz) 2'-OH 14.45(1H,br,s) 3'-OCH 3 3.89(3H,s) 4',6'-2H 7.00(2H,m) 7'-H 8.21(1H,s) MS(m/z): 456(M + 2,79), 454(M + ,7a), 441[(M + +2)-CH 3 , 40], 439(M + -CH 3 ,42), 401(7), 399(8), 285(14), 239(24), 226(100), 210(33), 197(37), 83(84). IR(KBr): 3431, 1660, 1624, 1471, 1252 cm -1 . Example 4. Preparation of derivative No. 15 Compound (I) (0.5 mmole) was weight out into 50 µl three-neck flask. 20 ml of anhydrous pyridine was added to dissolve compound (I). While cooling in ice-bath, o-phthalic acid anhydride was added. The mixture was stirred overnight at room temperature. When thin-layer chromatography determination indicated substantial completion of the reaction, the pressure was reduced by means of water pump to vaporize pyridine. Separation was carried out using silica gel layer chromatography. The development agent dichloromethane : methanol = 3 : 1 was used to produce the crude product, which was recrystallized using propanol to produce white powders of derivative No. 15 with 78% yield. The same process was used to prepare derivatives No. 1 to No. 16. 1 H NMR(d 6 -DMSO) : 3-H 6.09(1H,d,J=9.4Hz) 6-H 2 2.51(2H,s) 8-H 5.44(1H,d,J=4.8Hz) 9-H 3.56(1H,m) 10 a -H 2.66(1H,dd,J=16.8, 4.6Hz) 10 b -H 2.09(1H,d,J=16.8Hz) 12-H 3 1.51(3H,s) 13-H 5.60(1H,q,J=6.8Hz) 14-H 3 1.62(3H,d,J=6.8Hz) 3',4',5' and 4-H 7.51(4H,m) 6'-H 7.73(1H,d,J=7.5Hz) N-H(amide) 7.90(1H,br,s) COO-H 8.46(1H,br,s) IR: υ max 3650-2400, 1710, 1655, 1605, 1546, 1450, 1300 cm -1 MS m/z: 372(M + ), 357, 343, 329, 242, 227, 187, 147, 104(100). Example 5. Preparation of derivative No. 44 Under argon gas stream 150 mg (0.620 mmole) of huperzine A and 200 mg of 4A molecular sieve were suspended in 4 ml of benzene. 76 µl (0.86 mmol) of pyridine-3-acetaldehyde and 20 mg of p-toluene sulphonic acid monohydrate were added. After reflux for three hours, the mixture was allowed to cool, and then neutralized with triethyl amine. The reaction solution was filtered with celite. After concentration, the residue was refined through silica gel column chromatography (methanol : dichloromethane = 1 : 20) to produce derivative No. 44, a colorless solid (183 mg, 89% yield). The same process was used to prepare derivatives No. 45 and No. 46, with 84% and 82% yield respectively. Derivative No. 44 NMR(CDCL 3 ) 1.64(3H,d,J=7.0Hz), 1.65(3H,s) 2.25(1H,d,J=16.0Hz), 2.82(1H,d,J=17.0Hz) 2.86(1H,d,J=16.0Hz), 3.07(1H,dd,J=5.0,17.0Hz) 8.65-3.75(1H,m) 5.14(1H,q,J=7.0Hz), 5.50(1H,d,J=5.0Hz) 6.34(1H,d,J=8.5Hz), 7.09(1H,d,J=9.5Hz) 7.40(1H,dd,J=5.0,8.0Hz), 8.28(1H,dt,J=2.0,8.0Hz), 8.47(1H,s) 8.70-8.72(1H,m), 8.94-8.96(1H,m), MS: 331(M + ), 316(base), 226 HRMS calculated value: molecular formula C 22 H 21 N 2 O(M + ): 331.16846 experimental value: 331.16888 Derivative No. 45 NMR(CDCL 3 ) 1.64(3H,d,J=7.0Hz), 1.65(3H,s) 2.25(1H,d,J=16.0Hz), 2.82(1H,d,J=16.5Hz) 2.86(1H,d,J=16.0Hz), 3.07(1H,dd,J=5.0,16.5Hz),3.61-3.70(1H,m) 5.10(1H,q,J=7.0Hz), 5.50(1H,d,J=4.0Hz) 6.39(1H,d,J=9.5Hz), 7.05(1H,d,J=9.5Hz) 7.11-7.73(2H,m), 8.41(1H,s), 8.73-8.79(2H,m), MS: 331(M + ), 316(base), 226 HRMS calculated value: molecular formula C 22 H 21 N 3 O(M + ): 331.16846 experimental value: 331.18836 Derivative No. 46 NMR(CDCL 3 ) 1.64(3H,d,J=6.5Hz), 1.65(3H,s) 2.24(1H,d,J=16.0Hz), 2.82(1H,d,J=16.5Hz) 2.85(1H,d,J=16.0Hz), 3.07(1H,dd,J=5.0,16.5Hz),3.67-3.70(1H,m) 3.96(6H,s), 5.22(1H,q,J=6.5Hz), 5.30(1H,s) 5.47-5.49(1H,m), 6.39(1H,d,J=9.5Hz), 7.12(1H,s), 7.15(1H,d,J=9.5Hz), 8.29(1H,s) MS: 406(M - ,base), 391, 228, 167 HRMS calculated value: molecular formula C 24 H 26 N 2 O 4 (M + ): 406.18926 experimental value: 406.18949

Claims: A huperzine A derivative having the following structural formula wherein: either Y is -C=O and R 11 is H or C 1-5 alkyl; or Y and R 11 together form the group =CH; R is (in which n is zero or 1), (in which X is hydrogen, C 1-5 alkyl, C 1-5 alkyloxy, nitro, halogen, carboxy, alkyloxycarbonyl, hydroxymethyl, hydroxy, amino substituted by bis - C 1-5 alkyl); the group -(CH 2 ) m COOZ (in which m=0-5 and Z is hydrogen or C 1-5 alkyl); the group -CH=CH-G (in which G is phenyl, furanyl, carboxy or alkyloxycarbonyl); or dihydro or tetrahydropyridyl substituted at the nitrogen atom by C 1-5 alkyl; and R 1 is hydrogen, C 1-5 alkyl, pyridoyl or benzoyl substituted by C 1-5 alkyloxy. A huperzine A derivative according to claim 1, wherein Y is C=O and R 11 is H or C 1-5 alkyl; R is in which n=0 or 1 and X is hydrogen, C 1-5 alkyloxy, carboxy, alkyloxycarbonyl, pyridyl, dihydro or tetrahydropyridyl substituted at the nitrogen atom by C 1-5 alkyl; the group -(CH 2 ) m COOZ (in which m=0-5 and Z is hydrogen or C 1-5 alkyl); or the group -CH=CH-G (in which G is phenyl, furanyl, carboxy or alkyloxycarbonyl); and R 1 is hydrogen, C 1 -C 5 alkyl, pyridoyl or benzoyl substituted by C 1 -C 5 alkyloxy. A huperzine A derivative according to claim 1, wherein Y and R 11 together form the group =CH, R is or X is hydrogen, C 1-5 alkyl, C 1-5 alkyloxy, nitro, halogen, hydroxy, hydroxymethyl, amino substituted by bis C 1-5 alkyl; or the group -CH=CH-G (in which G is phenyl or furanyl); and R 1 is hydrogen or C 1-5 alkyl. A huperzine A derivative according to any preceding claim wherein R is the group which group represents a mono-, di- or tri- substituted phenyl group. A huperzine A derivative of the formula (II), which formula (II) is given in claim 1, wherein each of Y, R 11 , R and R 1 is as follows A huperzine A derivative according to claim 4 of the formula A process for preparing a huperzine A derivative according to any preceding claim, characterized in that : referring to the formula (II), given and defined in claim 1, (1) when Y is C=O, condensation is carried out between huperzine A and the corresponding substituted acyl chloride or acid anhydride in an anhydrous solvent; and (2) when Y and R 11 together form the group =CH, condensation is carried out between huperzine A and the corresponding substituted aldehyde in an anhydrous solvent. A pharmaceutical composition comprising a huperzine A derivative according to any one of claims 1 to 5, and a pharmaceutically acceptable excipient. A pharmaceutical composition comprising a huperzine A derivative of the formula given in claim 6 and a pharmaceutically acceptable excipient. A huperzine A derivative according to any one of claims 1 to 5 for use as a pharmaceutical. A huperzine A derivative according to claim 10 for use in the treatment of presenile dementia. A huperzine A derivative according to claim 6 for use as a pharmaceutical. A huperzine A derivative according to claim 12 for use in the treatment of presenile dementia. Use, in the manufacture of a medicament for the treatment of presenile dementia, of a huperzine A derivative according to any one of claims 1 to 5. Use, in the manufacture of a medicament for the treatment of presenile dementia, of a huperzine A derivative according to claim 6.

Inventors: JIANG SHANHAO, LIN JINLAI, NISHIMURA HIROAKI, SHEN JINGKANG, TANAKA KAZUHIRO, TANG XICAN, WAKANATSU TAKESHI, WU GUANSONG, YAMAGUCHI TAKUJI, ZHU CHENG, ZHU DAYUAN, JIANG, SHANHAO, LIN, JINLAI, NISHIMURA, HIROAKI, SHEN, JINGKANG, TANAKA, KAZUHIRO, TANG, XICAN, WAKANATSU, TAKESHI, WU, GUANSONG, YAMAGUCHI, TAKUJI, ZHU, CHENG, ZHU, DAYUAN, NISHIMURA, Hiroaki c/o Tsumura &amp; Co., WAKANATSU, Takeshi c/o Tsumura &amp; Co., YAMAGUCHI, Takuji c/o Tsumura &amp; Co.
Applicants: SHANGAHI INST MATERIA MEDICA, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Application year: 1995
Main classification: C07D221
IPC codes: A61P21, A61K31, A61P25, C07D401, A61K36, C07D405, C07D221